Trump Presses to Bring Chips and Generic Drugs Home

President Trump’s campaign to pull strategic manufacturing back to the United States is now bearing down on two very different corners of the global economy at once: the factories that make the hardware behind the artificial-intelligence boom, and the plants that churn out the world’s low-cost generic medicines.

In recent days, the administration has sharpened that effort with a familiar mix of tariff threats, public pressure and demands for domestic investment. Taiwan Semiconductor Manufacturing Company, the world’s dominant contract chipmaker, said it would add another $100 billion to its Arizona expansion, bringing its announced U.S. commitment to roughly $265 billion. In Texas, Wistron, a Taiwanese electronics manufacturer, opened a $700 million plant in Fort Worth to assemble Nvidia-powered AI systems for the American market.

At nearly the same time, Mr. Trump outlined a sweeping new tariff path for imported generic drugs: zero tariffs for two years starting Aug. 1, 2026, then 100 percent for one year, and 200 percent after that. The delayed timetable is meant to give drugmakers time to move production to the United States before the steep duties take effect.

Taken together, the moves amount to one of the clearest expressions yet of the administration’s industrial-policy strategy. Rather than relying mainly on subsidies or tax incentives, the White House is increasingly using the threat of lost access to the American market to try to rewire supply chains for products it sees as economically or strategically vital.

Pressure on the AI supply chain

The semiconductor push has become especially urgent as demand for AI computing has surged and as Washington has sought to reduce dependence on manufacturing concentrated in Taiwan and elsewhere in Asia.

TSMC’s latest Arizona commitment extends a yearslong effort by the United States to build a domestic chip base, but it also underscores the tension at the center of Mr. Trump’s approach. The administration wants more of the most valuable production on American soil; the companies involved have repeatedly said the United States remains a more expensive and difficult place to build than their established Asian hubs.

TSMC has said demand for AI chips remains strong, but it has also pointed to labor shortages and other execution challenges in the United States. The company has made clear in past statements that Taiwan remains its most efficient manufacturing base even as it expands abroad. That leaves a central question unresolved: how much of the most advanced chipmaking ecosystem — not just fabrication, but packaging, suppliers and skilled labor — can be transplanted quickly enough to satisfy Washington’s ambitions.

Wistron’s new Texas facility offers a glimpse of what that broader ecosystem could look like if the administration’s pressure campaign succeeds. The Fort Worth plant will assemble Nvidia AI systems, including products based on the GB300 platform, adding another link in the U.S. chain for the data-center hardware driving the AI boom. Investors appeared to welcome the move, sending Wistron shares higher in Taiwan.

For the White House, such announcements are political as well as industrial victories. They allow Mr. Trump to argue that foreign companies, particularly from Taiwan, are investing in America because they believe access to the U.S. market increasingly requires a physical presence inside it.

A new front in pharmaceuticals

The generic-drug tariffs open a more complicated and potentially riskier chapter.

In April, the administration imposed 100 percent tariffs on many branded imported medicines unless companies cut prices or committed to producing in the United States. Generic drugs had initially been spared. Now they, too, are being pulled into the same framework, though on a delayed schedule.

The phase-in reflects the reality that generic medicines are a different kind of supply-chain challenge from advanced chips. They are lower-margin products, often made through sprawling international networks optimized for cost. India has become one of the most important suppliers to the United States, alongside other overseas producers. Recreating that manufacturing base domestically would be far more difficult than ordering a handful of high-profile corporate investments.

The administration is betting that the long lead time before the tariffs bite will be enough to force a realignment. But analysts and industry executives have long warned that generic production is notoriously price-sensitive, and that manufacturers may struggle to justify building American plants unless they can be assured of higher prices or long-term policy stability.

That raises the stakes for hospitals, pharmacies and patients. If production cannot move fast enough, the tariff schedule could increase costs or worsen shortages in a market already prone to thin inventories and supply disruptions. Whether the White House ultimately grants exemptions, delays or revisions before the duties escalate in August 2028 remains uncertain.

Why this matters now

What links AI chips and generic drugs is not the technology or the economics, but the administration’s view that both belong in a category of strategic dependence the United States can no longer tolerate.

For semiconductors, the concern is geopolitical and technological: the most advanced chips sit at the heart of military systems, cloud computing and the AI race, while much of the world’s cutting-edge production remains concentrated near a potential flashpoint in the Taiwan Strait. For medicines, the concern is resilience: the United States relies heavily on overseas manufacturing for the everyday drugs that underpin basic care.

Mr. Trump has made those vulnerabilities central to his economic agenda, particularly as he heads toward the midterm campaign with a message built around jobs, industrial strength and supply-chain security. The result is a more aggressive version of onshoring policy — one that uses access to the American consumer market as leverage not just to encourage domestic production, but to compel it.

Whether that strategy succeeds may depend on forces the White House cannot easily command: the pace of construction in Arizona and Texas, the availability of skilled workers, the economics of generic-drug production and the willingness of multinational companies to bet that today’s tariffs will endure long enough to justify costly relocation.

For now, though, the direction is unmistakable. From AI servers in Fort Worth to pill production plans not yet drawn on factory floors, the administration is trying to redraw the map of where critical goods are made — and to do it on Washington’s timetable.